Send us a text

Surfing NASH returns to its regular program with a fresh episode and some fascinating and progressive ideas around non-invasive testing. Mazen Noureddin joins co-hosts Jörn Schattenberg, Louise Campbell and Roger Green to discuss serum identification of at-risk MASH and the Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF). In late July, Mazen co-authored a paper on the subject which was published in Hepatology.

This final conversation starts with Louise’s curiosity on whether any socioeconomic differences were clear between those considered at-risk. Mazen responds with his belief that there would be much to benefit from studying a larger prospective cohort with multiple different ethnic groups. Before moving on to final thoughts, Roger asks Mazen whether there are any populations yet to be considered that might benefit from this work going forward. Mazen responds by highlighting the importance of continued and persistent testing and reiterates that the next steps have more to do with response to therapy and correlation with outcomes. Jörn lastly mentions that the cirrhotic patient population would benefit from a test to which Mazen offers a clarifying response on when and why this group was included in the study. 

In closing, Roger asks the group, starting with Mazen, to envision the practical use of MASEF two years from today. Each panelist provides a thought-provoking answer - surf on to learn more.

If you have questions or comments around MASEF, metabolomics or any other ideas considered in this episode, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at [email protected]. The Surfing the NASH Tsunami will be back next week with more original content.

Stay Safe and Surf On!